Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms.

ABSTRACT: Despite being infrequent tumors, the incidence and prevalence of pancreatic neuroendocrine tumors (P-NETs) has been rising over the past few decades. In recent years, rigorous phase III clinical trials have been conducted, allowing the approval of several drugs that have become the standard of care in these patients. Although various treatments are used in clinical practice, including somatostatin analogues (SSAs), biological therapies like sunitinib or everolimus, peptide receptor radionuclide therapy (PRRT) or even chemotherapy, a consensus regarding the optimal sequence of treatment has not yet been reached. Notwithstanding, sunitinib is largely used in these patients after the promising results shown in SUN111 phase III clinical trial. However, both prompt progression as well as tumor

SUBMITTER: Pozas J 

PROVIDER: S-EPMC6801829 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature